CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Pompano Beach, FL, Nov. 07, 2017 -- BioStem Technologies, Inc. (OTC PINK: BSEM) (the “Company”) announced today that, Qualified Pharma Ingredients, Inc. (QPI), an Active Pharmaceutical Ingredients supplier, has begun expansion of its facility to 4,500 square feet. The construction is expected to take 6 weeks and will provide additional product storage, pack out stations, and a Schedule III-V DEA cage, allowing QPI to expand its product portfolio to include DEA regulated products.
DrDavesBest.com has launched a newly developed, marketing optimized website for the Company’s e-commerce division. The Company recently launched a marketing initiative to grow the sales of its nutraceutical products, including the hiring of an in-house marketing executive. Company CEO, Henry Van Vurst stated, “One of our first strategic moves in expanding our customer base is to attract a younger market, and we are eager to see how the new look and navigation tools perform.”
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc., is a global life sciences corporation, focused on providing world-class technologies with a concentration in Pharmaceuticals, Wellness, Regenerative Medicine and Blue Technologies. We continuously innovate through the inclusion of complementary companies and a diversified technology portfolio. This improves the Quality of Life for our consumers and, as a result, maximizes shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” believe” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
CONTACT INFORMATION BioBlue Technologies, Inc.: Phone: 954-380-8342 Website: https://biobluetechnologies.com/ Email: [email protected] Twitter: @Biostemtech Facebook: BioStem Technologies Investor Relations: Andrew Van Vurst [email protected] 954.380.8342
